title: The role of chemotherapy in the treatment of patients with brain metastases from solid tumors.
abstract: Brain metastases are the most frequent cancer in the central nervous system, being ten times more common than primary brain tumors. Patients generally have a poor outcome with a median survival of 4 months after diagnosis of the metastases. Therapeutic options include surgery, stereotactic, radiosurgery, whole-brain radiotherapy (WBRT), and chemotherapy. Patients with a limited number of brain metastases and well-controlled systemic cancer benefit from brain metastases-specific therapies, including surgery, radiosurgery, and conventional radiation. The role of chemotherapy for brain metastases remains limited. There is concern about drug delivery because of the blood-brain barrier. However, higher response rates are noted with initial therapies, suggesting that part of the poor response rate may be related to the late onset of brain metastases and the use of second- and third-line regimens. Recent studies have demonstrated objective responses with systemic therapy in a variety of cancer types, especially when combined with WBRT. Individual therapeutic strategies for central nervous system metastases must be chosen based on performance status, the extent of intracranial disease, and the chemosensitivity of the underlying tumor, as well as the control of the systemic cancer. In this article we review important prognostic factors and challenges in using chemotherapy. We specifically review recent advances in the treatment of brain metastases from breast and lung cancer as well as melanoma. Future treatment advances will require a multidisciplinary approach integrating surgical, radiation, and chemotherapeutic options to improve neurological function and quality of life, rather than just focusing on survival endpoints.
authors.affiliation: Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
authors.forename: Tobias
authors.initials: T
authors.lastname: Walbert
authors.forename: Mark R
authors.initials: MR
authors.lastname: Gilbert
mesh_terms: D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000378:metabolism; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000556:secondary; D017024:Chemotherapy, Adjuvant; D016371:Cranial Irradiation; D019317:Evidence-Based Medicine; D006801:Humans; D019635:Neurosurgical Procedures; D018579:Patient Selection; D011788:Quality of Life; D018714:Radiotherapy, Adjuvant; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
references.citation: J Neurooncol. 2006 Jul;78(3):277-80
references.pmid: 16614943
references.citation: Eur J Cancer. 1993;29A(12):1696-9
references.pmid: 7691116
references.citation: J Clin Oncol. 2003 Jul 1;21(13):2551-7
references.pmid: 12829675
references.citation: Melanoma Res. 2003 Feb;13(1):97-103
references.pmid: 12569292
references.citation: J Clin Oncol. 2000 Oct 1;18(19):3400-8
references.pmid: 11013281
references.citation: Cancer. 2004 Oct 15;101(8):1760-6
references.pmid: 15386311
references.citation: Cancer. 1981 Jul 15;48(2):384-94
references.pmid: 7237407
references.citation: Ann Oncol. 2001 Feb;12(2):249-54
references.pmid: 11300333
references.citation: Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):297-302
references.pmid: 10661335
references.citation: Ann Oncol. 1993 Aug;4(7):579-83
references.pmid: 8395873
references.citation: Br J Cancer. 1990 Jan;61(1):147-50
references.pmid: 2153393
references.citation: J Clin Oncol. 2007 Jun 1;25(16):2306-12
references.pmid: 17538177
references.citation: J Clin Oncol. 1999 Nov;17(11):3522-30
references.pmid: 10550150
references.citation: Ann Oncol. 2006 Jun;17(6):952-6
references.pmid: 16565212
references.citation: Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):795-803
references.pmid: 10098435
references.citation: Lung Cancer. 1998 May;20(2):85-91
references.pmid: 9711526
references.citation: J Cancer Res Clin Oncol. 2002 Apr;128(4):214-8
references.pmid: 11935312
references.citation: Oncology. 2003;64(1):28-35
references.pmid: 12457029
references.citation: CNS Drugs. 2002;16(5):325-38
references.pmid: 11994022
references.citation: J Neurooncol. 1994;20(2):121-39
references.pmid: 7807190
references.citation: Ann Oncol. 2003 Jul;14(7):1072-7
references.pmid: 12853349
references.citation: Cancer. 1990 Nov 1;66(9):1873-8
references.pmid: 2224783
references.citation: Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51
references.pmid: 9128946
references.citation: Cancer. 2002 May 15;94(10):2698-705
references.pmid: 12173339
references.citation: J Clin Oncol. 2002 Sep 1;20(17):3644-50
references.pmid: 12202665
references.citation: Ann Oncol. 2004 Jul;15(7):1042-7
references.pmid: 15205197
references.citation: Ann Oncol. 2006 Sep;17(9):1412-7
references.pmid: 16790516
references.citation: Med Oncol. 2000 Nov;17(4):279-86
references.pmid: 11114706
references.citation: Clin Cancer Res. 2009 Feb 15;15(4):1452-9
references.pmid: 19228746
references.citation: Curr Oncol Rep. 2001 Nov;3(6):463-6
references.pmid: 11595113
references.citation: Cancer Invest. 2002;20(3):293-302
references.pmid: 12025223
references.citation: Cancer Treat Rep. 1981 Sep-Oct;65(9-10):811-4
references.pmid: 6268295
references.citation: Eur J Cancer. 2003 Jun;39(9):1271-6
references.pmid: 12763216
references.citation: Crit Rev Oncol Hematol. 2001 Jan;37(1):61-7
references.pmid: 11164720
references.citation: J Clin Oncol. 2005 Mar 1;23(7):1530-7
references.pmid: 15735128
references.citation: Cancer. 2005 Jun 15;103(12):2590-7
references.pmid: 15861414
references.citation: Lung Cancer. 2005 Nov;50(2):247-54
references.pmid: 16039010
references.citation: Lung Cancer. 2004 Oct;46(1):107-11
references.pmid: 15364138
references.citation: Ann Oncol. 2001 Jan;12(1):59-67
references.pmid: 11249050
references.citation: Arch Neurol. 1988 Jul;45(7):741-4
references.pmid: 3390029
references.citation: Lung Cancer. 1998 May;20(2):93-8
references.pmid: 9711527
references.citation: J Clin Oncol. 2006 May 1;24(13):2079-83
references.pmid: 16648509
references.citation: Cancer. 2008 Nov 1;113(9):2524-31
references.pmid: 18798231
references.citation: J Clin Oncol. 2004 Jun 1;22(11):2101-7
references.pmid: 15169796
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1648-55
references.pmid: 17363517
references.citation: J Clin Oncol. 1989 Jul;7(7):916-22
references.pmid: 2544685
references.citation: Cancer. 1986 Aug 15;58(4):832-9
references.pmid: 3755076
references.citation: Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1001-6
references.pmid: 10863071
references.citation: Anticancer Drugs. 2007 Jan;18(1):23-8
references.pmid: 17159499
references.citation: Cancer. 1992 Feb 15;69(4):972-80
references.pmid: 1735089
references.citation: Oncology. 2000 Nov;59(4):291-5
references.pmid: 11096340
references.citation: Cancer. 1996 Oct 15;78(8):1781-8
references.pmid: 8859192
references.citation: Ann Oncol. 2006 Oct;17(10):1592-7
references.pmid: 17005632
references.citation: J Clin Oncol. 2004 Sep 1;22(17):3608-17
references.pmid: 15337811
references.citation: J Neurooncol. 2005 Jan;71(1):61-5
references.pmid: 15719277
references.citation: J Neurooncol. 2001 Jul;53(3):259-65
references.pmid: 11718258
references.citation: Br J Cancer. 2007 Jan 15;96(1):44-8
references.pmid: 17146474
references.citation: Cancer. 1999 Apr 1;85(7):1599-605
references.pmid: 10193952
references.citation: J Clin Oncol. 2004 Jul 15;22(14):2865-72
references.pmid: 15254054
references.citation: Cancer Treat Res. 2007;136:1-21
references.pmid: 18078262
references.citation: Eur J Cancer. 2002 Sep;38(13):1724-9
references.pmid: 12175688
references.citation: Cancer. 2006 Jun 1;106(11):2445-51
references.pmid: 16639739
references.citation: Neurol Clin. 2003 Feb;21(1):1-23, vii
references.pmid: 12690643
references.citation: Oncologist. 2007 Jul;12(7):766-73
references.pmid: 17673608
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: Cancer. 1979 Nov;44(5):1913-8
references.pmid: 498057
references.citation: Oncologist. 2004;9(1):68-79
references.pmid: 14755016
references.citation: Cancer. 2006 Sep 15;107(6):1348-54
references.pmid: 16909414